Cargando…

Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 Diabetes

OBJECTIVE: Insulin detemir lacks the usual propensity for insulin to cause weight gain. We investigated whether this effect was a result of reduced energy intake and/or increased energy expenditure. RESEARCH DESIGN AND METHODS: A 32-week, randomized crossover design trial was undertaken in 23 patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zachariah, Sunil, Sheldon, Ben, Shojaee-Moradie, Fariba, Jackson, Nicola C., Backhouse, Katharine, Johnsen, Sigurd, Jones, Richard H., Umpleby, A. Margot, Russell-Jones, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120205/ https://www.ncbi.nlm.nih.gov/pubmed/21593292 http://dx.doi.org/10.2337/dc11-0098

Ejemplares similares

Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
por: Whyte, Martin B, et al.
Publicado: (2018)

Prandial Hypertriglyceridemia in Metabolic Syndrome Is Due to an Overproduction of Both Chylomicron and VLDL Triacylglycerol
por: Shojaee-Moradie, Fariba, et al.
Publicado: (2013)

Weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?
por: Russell‐Jones, D., et al.
Publicado: (2015)

The fat mass and obesity-associated (FTO) gene allele rs9939609 and glucose tolerance, hepatic and total insulin sensitivity, in adults with obesity
por: de Soysa, Ann Kristin Hjelle, et al.
Publicado: (2021)

The Effect of Fructose Feeding on Intestinal Triacylglycerol Production and De Novo Fatty Acid Synthesis in Humans
por: Steenson, Simon, et al.
Publicado: (2020)

Exploring the determinants of ethnic differences in insulin clearance between men of Black African and White European ethnicity
por: Ladwa, Meera, et al.
Publicado: (2021)

Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague–Dawley rats
por: Rojas, J M, et al.
Publicado: (2011)

Ethnic differences in beta cell function occur independently of insulin sensitivity and pancreatic fat in black and white men
por: Ladwa, Meera, et al.
Publicado: (2021)

Reduced Efficacy of Insulin Detemir in Controlling Hyperglycemia during Pregnancy: An Interesting Case Report
por: Pande, Arun, et al.
Publicado: (2018)

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
por: Hodson, L, et al.
Publicado: (2017)

Erratum: Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
por: Hodson, L, et al.
Publicado: (2017)

Insulin Detemir Causes Lesser Weight Gain in Comparison to Insulin Glargine: Role on Hypothalamic NPY and Galanin
por: Zafar, Mohammad Ishraq, et al.
Publicado: (2014)

Black African men with early type 2 diabetes have similar muscle, liver and adipose tissue insulin sensitivity to white European men despite lower visceral fat
por: Bello, Oluwatoyosi, et al.
Publicado: (2019)

Euglycemic Infusion of Insulin Detemir Compared With Human Insulin Appears to Increase Direct Current Brain Potential Response and Reduces Food Intake While Inducing Similar Systemic Effects
por: Hallschmid, Manfred, et al.
Publicado: (2010)

Impact of liver fat on the differential partitioning of hepatic triacylglycerol into VLDL subclasses on high and low sugar diets
por: Umpleby, A. Margot, et al.
Publicado: (2017)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes
por: Philips, Jean-Christophe, et al.
Publicado: (2006)

Cerebrocortical Beta Activity in Overweight Humans Responds to Insulin Detemir
por: Tschritter, Otto, et al.
Publicado: (2007)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander, Priscilla A
Publicado: (2012)

Insulin Detemir in Pregnancy: A Small but Significant Step Forward?
por: McElduff, Aidan
Publicado: (2012)

The role of insulin detemir in overweight type 2 diabetes management
por: Demssie, Yared N, et al.
Publicado: (2009)

Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study
por: Yale, Jean-François, et al.
Publicado: (2013)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16 Years
por: Thalange, Nandu, et al.
Publicado: (2016)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

Sustained Treatment with Insulin Detemir in Mice Alters Brain Activity and Locomotion
por: Sartorius, Tina, et al.
Publicado: (2016)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Maharashtra cohort of the A(1)chieve study
por: Phadke, Uday, et al.
Publicado: (2013)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Biphasic insulin aspart‐30 reduces glycemic variability to a greater degree than insulin detemir: A randomized controlled trial of once‐daily insulin regimens using continuous glucose monitoring
por: Tsujino, Daisuke, et al.
Publicado: (2017)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes
por: Hayakawa, Taro, et al.
Publicado: (2011)

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes
por: Philis-Tsimikas, Athena
Publicado: (2008)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
por: Peterson, Gregory E
Publicado: (2009)

Safety and Effectiveness of Insulin Detemir in Different Age-Groups in the A(1)chieve Study
por: Malek, Rachid, et al.
Publicado: (2013)

Insulin detemir may be less efficacious in patients with nonalcoholic fatty liver disease and hypertriglyceridemia
por: Whyte, Martin, et al.
Publicado: (2015)

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the West India cohort of the A(1)chieve study
por: Jain, Sunil M., et al.
Publicado: (2013)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
por: Asias, Bernadette D., et al.
Publicado: (2015)

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK
por: Thalange, Nandu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9dgsrqc3g3b1e13lo7b3viqiff